"Most companies polled by the Berenberg team said they had minimal exposure, including Amicus Therapeutics, Kymera Therapeutics, CureVac, Repare Therapeutics and Affimed. Those that do have business with SVB said their depositis were mostly for short-term operating expenses. These companies already had, or were in the process of moving their money elsewhere..."
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, ...
- AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023
- AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meeting
- AFM24: Data from the three ongoing studies expected to be presented at scientific conferences in Q2 or Q3 of 2023
- AFM28: Clinical phase 1 study is open and recruiting; clinical trial applications now approved in four European countries including Belgium, France, Denmark and Spain
- Anticipated cash runway into 2025: As of December 31, 2022, cash and cash equivalents were €190.3 million
Das Problem scheint das EPS, dass stark von den Analoerwartungen abweicht. -0,60 zu -0,19 Der massiv höhere Umsatz (als erwartet) spielt offenbar leider keine Rolle.
AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in Intent...
iTechDachs
: Vermutlich waren die Daten noch nicht vorhanden
oder noch zu vorläufig - Stichtag war der 15 Februar bzw. Abgabe für late-breaking 15-te März. (Es gibt scheinbar überhaupt nur einen late-breaker Abstract auf der ASCO dieses Jahr.)
Welche Überraschungen erwartest Du bei den Zahlen? Wenn ich mir die Bewertung von Affimed anschaue und den Cash-Bestand am oberen Ende der Biotech-Nahrungskette, dann sehe ich hier ein leckeres Häppchen.
HEIDELBERG, Germany, May 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company...
Thread abonnieren
